BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.
2L PILOT trial
Number of responders‡ | 49/61 |
DOR§ | |
Median (months) | 11.2 |
(95% CI)¶ | 5.1, NR |
Range | 0.0+ to 22.8+ |
DOR if best overall response is CR | |
Median (months) | NR |
(95% CI)¶ | 11.2, NR |
Range | 2.0+ to 22.8+ |
DOR if best overall response is PR | |
Median (months) | 2.10 |
(95% CI)¶ | 1.4, 2.3 |
Range | 0.0+ to 7.9+ |
Characteristics1,3 | (N=61) |
---|---|
Age; range | 74 years; 53-84 years |
ECOG PS 0/1/2 at screening | 30%/44%/26% |
Primary refractory | 53% |
Relapsed | 47% |
LBCL subtypes | |
DLBCL, NOS | 51% |
High-grade B-cell lymphoma | 33% |
DLBCL transformed from follicular lymphoma | 15% |
Rates of survival in the PILOT trial2* | Median months (95% CI) |
---|---|
PFS | 9.03 (4.17, NR)† |
EFS | 7.23 (3.22, 22.6)‡ |
OS | NR (17.28, NR)§ |
This website is best viewed
using the horizontal display on
your tablet device.
This website is best viewed
using the vertical display on
your mobile device.